Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 842 across all filing types
Latest filing 2024-09-23 Capital/Financing Update
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Bioxyne Extends Contract with Aura Therapeutics 3 pages 196.8KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 24 September 2024 from Bioxyne Limited regarding an amendment to an existing manufacturing and supply agreement with a customer. It details operational updates, contract terms, forecast sales, and company positioning in the pharmaceutical and cannabis manufacturing market. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is a corporate announcement about a contract amendment and operational update rather than a formal financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is not a regulatory filing or certification. The content is primarily a business update and contract amendment announcement. Therefore, the best fitting category is Capital/Financing Update (CAP), as it relates to a material contract amendment impacting expected sales and manufacturing volumes, which is a capital-related operational update.
2024-09-23 English
Bioxyne Investor Webinar 25 September 2024 2 pages 234.4KB
Investor Presentation Classification · 85% confidence The document is an announcement inviting shareholders and prospective investors to an online investor webinar hosted by the company's Managing Director. It provides details about the event, registration information, and contact details. There is no financial data, no detailed presentation content, no report attached or referenced as published, and no regulatory or voting information. The document is essentially an invitation and event announcement for an investor presentation but does not contain the presentation itself or detailed financial or strategic information. Therefore, it fits best under the category of Investor Presentation (IP) as it relates to a presentation event for investors, even though the actual presentation content is not included, the primary purpose is to inform about the investor-focused event.
2024-09-23 English
Announcement 21.8.2024 Clarifying Statement 3 pages 227.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 21 August 2024, providing clarifying information about a previously announced 2-year manufacture and supply agreement for medicinal cannabis pastilles. It includes details about the agreement terms, forecast revenue, deposit received, termination clauses, and payment terms. The document is an announcement clarifying and supplementing a prior announcement rather than a full financial report or detailed presentation. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not a regulatory certification or voting result. The content fits best as a Capital/Financing Update (CAP) because it relates to a significant commercial agreement impacting the company's revenue and operations, which is typical for financing or capital-related updates. The document length (5669 characters) and content confirm it is a substantive announcement rather than a brief report publication notice or regulatory filing. Therefore, the classification is CAP with high confidence.
2024-09-17 English
Reinstatement to Quotation 1 page 92.0KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from ASX Compliance regarding the reinstatement to quotation of Bioxyne Limited's securities. It mentions the lifting of suspension following a clarification announcement. The document is short (712 characters) and serves as an official notice rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed disclosures. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and compliance notices that do not fit other specific categories.
2024-09-17 English
Reinstatement to Quotation 1 page 92.0KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from ASX Compliance regarding the reinstatement to quotation of Bioxyne Limited's securities following a clarification announcement. It is a short notice about trading status and does not contain financial statements, management discussion, or detailed report content. It is not an annual report, earnings release, or any detailed financial or governance report. It is an official regulatory announcement related to trading status, fitting best under Regulatory Filings (RNS).
2024-09-17 English
Response to ASX Aware Query 7 pages 1.3MB
Regulatory Filings Classification · 95% confidence The document is an ASX Aware Letter dated 18 September 2024 from Bioxyne Limited responding to questions from ASX Compliance regarding a prior announcement about a significant supply agreement. The letter discusses compliance with ASX Listing Rules, continuous disclosure obligations, and ASIC Regulatory Guide 170 concerning forward-looking financial information. It clarifies details about the contract, timing of disclosure, and the basis for forecasted revenue. The document is a regulatory compliance response to a market announcement and does not contain financial statements, earnings data, or management discussion of results. It is not a report itself but a regulatory filing addressing disclosure issues and compliance with listing rules. Therefore, it fits best under Regulatory Filings (RNS).
2024-09-17 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.